ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Theobromine on Blood Lipid Parameters in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01481389
Recruitment Status : Completed
First Posted : November 29, 2011
Last Update Posted : September 18, 2012
Sponsor:
Information provided by (Responsible Party):
Unilever R&D

Brief Summary:

The purpose of this study is to determine the effect of theobromine on blood lipid parameters in healthy subjects. Secondary objectives are to determine the effect of cocoa and an interaction effect of cocoa and theobromine on blood lipid parameters.

Hypothesis: theobromine has a positive effect on blood lipid parameters.


Condition or disease Intervention/treatment Phase
Cardiovascular Diseases Dietary Supplement: Theobromine Dietary Supplement: Cocoa Dietary Supplement: Cocoa and theobromine Dietary Supplement: Placebo Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 152 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effect of Theobromine on Blood Lipid Parameters in Healthy Subjects
Study Start Date : December 2010
Actual Primary Completion Date : January 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Theobromine

Arm Intervention/treatment
Active Comparator: Theobromine drink Dietary Supplement: Theobromine
200 ml drink with added theobromine (no cocoa added)

Active Comparator: Cocoa drink Dietary Supplement: Cocoa
200 ml drink with cocoa (no theobromine added)

Placebo Comparator: Placebo drink Dietary Supplement: Placebo
200 ml drink (no added theobromine or cocoa)

Active Comparator: Cocoa and theobromine drink Dietary Supplement: Cocoa and theobromine
200 ml drink with added cocoa and theobromine




Primary Outcome Measures :
  1. Blood lipids [ Time Frame: after 4 weeks intervention ]

Secondary Outcome Measures :
  1. Blood pressure [ Time Frame: After 4 weeks intervention ]
  2. Heart rate [ Time Frame: After 4 weeks intervention ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Apparently healthy men and post-menopausal women: no medical conditions which might affect study measurements (judged by study physician)
  • Willing and able to participate in the study protocol
  • Written informed consent
  • Age 40-70 years
  • 10-year risk of developing CHD <10%, based on data from the Framingham Heart Study
  • BMI > 18 and < 30 kg/m2
  • Blood pressure, heart rate, haematological and clinical chemical parameters within the normal reference range as judged by research physician
  • Willing to comply with the dietary restrictions of the study.
  • Accessible veins on arm(s) as determined by examination at screening

Exclusion Criteria:

  • Previous cardiovascular event(s) (stroke, TIA, angina, myocardial infarction, heart failure)
  • Diabetes mellitus
  • Reported alcohol consumption > 14 units/week (female) or > 21 units/week (male)
  • Currently on a medically prescribed diet, or slimming diet
  • Reported weight loss or gain of 10% body weight or more during a period of 6 months before pre-study examination
  • Reported intense sporting activities > 10 h/w
  • Use of prescribed medication which may interfere with study measurements, as judged by the physician
  • Use of antibiotics in the three months before screening or during the study.
  • Currently smoking or being a non-smoker for less than 6 months and reported use of any nicotine containing products in the 6 months preceding the study and during the study itself
  • Reported intolerance to test products or other food products provided during the study
  • Blood donation 1 month (males) or 2 months (females) prior to screening and during the study
  • Reported participation in another nutritional or biomedical trial 3 months before screening or during the study.
  • Extreme coffee consumption

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01481389


Locations
France
Eurofins Optimed
Gieres, France, 38610
Sponsors and Collaborators
Unilever R&D
Investigators
Study Director: Wieneke Koppenol, MSc Unilever R&D
Study Director: Nicole Neufingerl, MSc Unilever R&D

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Unilever R&D
ClinicalTrials.gov Identifier: NCT01481389     History of Changes
Other Study ID Numbers: 10022V
First Posted: November 29, 2011    Key Record Dates
Last Update Posted: September 18, 2012
Last Verified: September 2012

Keywords provided by Unilever R&D:
Blood lipids
risk factor for cardiovascular diseases

Additional relevant MeSH terms:
Cardiovascular Diseases
Theobromine
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Vasodilator Agents